Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray L, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley MS. Rubinstein JD, et al. Among authors: grimley ms. Blood Adv. 2022 May 10;6(9):2897-2907. doi: 10.1182/bloodadvances.2021006309. Blood Adv. 2022. PMID: 35108727 Free PMC article. Clinical Trial.
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R. Pulsipher MA, et al. Blood. 2009 Aug 13;114(7):1429-36. doi: 10.1182/blood-2009-01-196303. Epub 2009 Jun 15. Blood. 2009. PMID: 19528536 Free article. Clinical Trial.
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH. Marsh RA, et al. Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10. Biol Blood Marrow Transplant. 2013. PMID: 24035782 Free PMC article.
Bortezomib for refractory autoimmunity in pediatrics.
Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH. Khandelwal P, et al. Among authors: grimley ms. Biol Blood Marrow Transplant. 2014 Oct;20(10):1654-9. doi: 10.1016/j.bbmt.2014.06.032. Epub 2014 Jun 28. Biol Blood Marrow Transplant. 2014. PMID: 24979732 Free article. Clinical Trial.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Marsh RA, et al. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10. Biol Blood Marrow Transplant. 2015. PMID: 25865646 Free PMC article.
83 results